Click on a filter below to refine your search. Remove a filter to broaden your search.
A strong recommendation was given for the addition of an SGLT-2 or GLP-1 agonist to metformin, and lifestyle modifications.
A reduction was seen in risk for clinically important kidney outcomes and death from cardiovascular causes.